Extracted from this filing and checked against the source text.
Shareholder VotesSEC 8-K Item 5.07confidence 0.9
Denali Therapeutics Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm at the 2026-06-03 meeting.
Proposal
auditor ratification
Outcome
passed
Meeting
2026-06-03
Exact text from the filing
The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified based on the following results of voting:
Denali Therapeutics Inc. shareholders approved Election of three Class III directors at the 2026-06-03 meeting.
Proposal
director election
Outcome
passed
Meeting
2026-06-03
Exact text from the filing
Election of three Class III directors to hold office until the 2029 annual meeting of stockholders. Each of the following nominees was elected to serve as a Class III director, to hold office until the Company’s 2029 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier resignation or removal.
Denali Therapeutics Inc. shareholders approved Advisory vote to approve executive compensation at the 2026-06-03 meeting.
Proposal
say on pay
Outcome
passed
Meeting
2026-06-03
Exact text from the filing
Advisory Vote to Approve Executive Compensation The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.